News

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

– Plans for filing an IND was agreed with the FDA in a recent meeting – – Positive preclinical results…

11 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on…

11 months ago

MUHC Foundation launches $3 million palliative care campaign

The campaign honours Dr. Balfour Mount, the renowned Eric M. Flanders Emeritus Professor of Palliative Care at McGill University and…

11 months ago

Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand

Leading Independent Proxy Advisory Firms Recognize the Significant, Immediate and Certain Cash Value the Transaction Delivers to Avid StockholdersTUSTIN, Calif.,…

11 months ago

HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant

"Patent-Pending Technology Transforms Personal Healthcare Management" NAPLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB:…

11 months ago

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical…

11 months ago

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2…

11 months ago

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to…

11 months ago

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage…

11 months ago

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:…

11 months ago